---
title: "Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285857826.md"
description: "Hansoh Pharmaceutical has received Breakthrough Therapy Designation from China's National Medical Products Administration for its drug HS-20093, aimed at treating unresectable locally advanced or metastatic esophageal squamous cell carcinoma. This designation may expedite the drug's development and review process, enhancing Hansoh's position in oncology and expanding its late-stage pipeline. Analysts rate the stock (HK:3692) as a Buy with a price target of HK$47.00. Hansoh focuses on innovative drug development, particularly in oncology, addressing significant unmet medical needs in Asia."
datetime: "2026-05-11T00:08:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285857826.md)
  - [en](https://longbridge.com/en/news/285857826.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285857826.md)
---

# Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.

Hansoh Pharmaceutical has received Breakthrough-Therapy-Designated Drug status from China’s National Medical Products Administration for HS-20093, a self-developed B7-H3-targeted antibody-drug conjugate for injection. The proposed indication is for patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma who have failed first-line platinum-based chemotherapy and immune checkpoint inhibitor treatment.

The designation highlights regulatory recognition of HS-20093’s potential clinical benefit in a hard-to-treat cancer setting, and may accelerate its development and review timeline. This could strengthen Hansoh’s position in the oncology biologics and ADC segment, expand its late-stage pipeline, and potentially offer a new treatment option to ESCC patients with limited therapeutic alternatives.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

**More about Hansoh Pharmaceutical Group Company Limited**

Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on the research, development and commercialization of innovative drugs. The group develops oncology and other specialty medicines, leveraging in-house R&D capabilities and targeting major unmet medical needs in the domestic and potentially broader Asian healthcare markets.

**Average Trading Volume:** 9,352,240

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$219.8B

Learn more about 3692 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug](https://longbridge.com/en/news/286266501.md)
- [CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer](https://longbridge.com/en/news/285925629.md)
- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)
- [Bergman: ‘The time is now’ to push for breakthroughs in psychedelic treatments](https://longbridge.com/en/news/286946328.md)
- [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md)